Developer docs
API playgroundTry for free, no card

Search company profiles

Prenosis

Full company profile

uuid0000mdn

Namestring
Prenosis
Legal namestring
Prenosis, Inc.
Websiteurl
prenosis.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Prenosis is a Chicago-based AI diagnostics company founded in 2014 that develops precision medicine tools for acute care conditions, with its first commercial focus on sepsis. The company's lead product, the Sepsis ImmunoScore, is the first FDA-authorized AI diagnostic tool for sepsis (De Novo authorization, April 2024); it ingests 22 parameters including vital signs, routine labs, demographics, and biomarkers (CRP, procalcitonin) to predict sepsis onset and adverse outcomes within 24 hours, stratifying patients into four risk levels, and achieved an AUC of 0.82 in NEJM AI peer-reviewed validation. The Sepsis ImmunoScore is built on the Immunix precision medicine platform, which combines biological data from over 138,000 longitudinal blood specimens with clinical EMR data from 35,000+ patients collected across 11+ U.S. hospitals over more than a decade — claimed as the world's largest biological-clinical dataset for acute care patients with suspected infections.

Prenosis generates revenue through a combination of subscription/recurring AI diagnostic testing deployed via direct enterprise sales to hospital systems, platform licensing through an exclusive commercial distribution partnership with Roche Diagnostics via the Navify Algorithm Suite, and clinical trial network services supporting BARDA-funded studies. Its customer base is concentrated in U.S. large hospital systems, academic medical centers, and government healthcare programs (BARDA, NIH, DTRA), with the U.S. military and federal agencies representing adjacent non-dilutive funding channels. The company's primary GTM motions combine enterprise field sales targeting integrated delivery networks, channel distribution through Roche's established diagnostic footprint, and event-driven engagement with the sepsis and emergency medicine clinical community (Sepsis Alliance Summit, ACEP, World Sepsis Congress).

Strategically, Prenosis is positioned to extend beyond sepsis into adjacent acute care conditions (ARDS, AKI, AHF) using its Immunix platform, with a $20M BARDA Type to Treat Program contract funding expansion to up to 40 U.S. academic medical centers and a co-development collaboration with BioAegis Therapeutics for ARDS patient stratification. Recent milestones including SOC 2 Type II compliance (March 2026), a dedicated CMS ICD-10-PCS reimbursement code (effective October 2025), and a $20M Series A financing (January 2026) indicate the company is transitioning from a research-stage biobank operator to a scaled commercial diagnostics platform.

Short descriptiontext

Prenosis is a Chicago-based AI diagnostics company that developed Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, built on its Immunix precision medicine platform combining a 138,000+ specimen biobank with clinical data, sold to U.S. hospital systems and distributed via Roche Diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI sepsis diagnostics, precision medicine platform, acute care diagnostics, clinical decision support, biomarker-driven diagnostics
Industry1 code
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
AI Clinical Diagnostics for Acute Care
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI Diagnostic Testing
TypeSubscription Recurring
Description

Revenue generated from deployment of Sepsis ImmunoScore diagnostic tool to hospitals and healthcare systems. Tool integrates into hospital EMR workflow and generates risk assessments for patients.

prenosis.com
2Platform Licensing
TypeLicensing Royalties
Description

Licensing of Immunix platform technology through distribution agreement with Roche Diagnostics for access to Sepsis ImmunoScore via Navify Algorithm Suite.

prenosis.com
3Clinical Trial Services
TypeProfessional Services
Description

Precision medicine clinical trial network services enabling rapid identification of patients with specific biological profiles for therapeutic clinical trials, supporting BARDA-funded studies.

prenosis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Immunix®
Description

Precision medicine platform that enables the development and validation of new precision medicine solutions and their real-time implementation in clinical workflows.

prenosis.com
+1 more record
Core offering1 text field

Prenosis develops and sells AI-powered diagnostic and predictive tools for acute care, primarily through its Sepsis ImmunoScore® product, the first FDA-authorized AI diagnostic for sepsis. The product is built on the proprietary Immunix® precision medicine platform that combines biological data from a large biobank with clinical EMR data. Products are sold to hospital systems via direct enterprise sales and through a distribution partnership with Roche Diagnostics, integrating directly into hospital EMRs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 15% higher accuracy in identifying patients meeting Sepsis-3 criteria compared to provider assessment alone
+4 more records
Product overview1 text field

Prenosis offers a two-product portfolio built on its Immunix precision medicine platform: the Immunix platform itself (a biomarker-clinical data platform powering AI diagnostics) and Sepsis ImmunoScore (the first FDA-authorized AI diagnostic tool for sepsis, built on Immunix). Sepsis ImmunoScore integrates directly into hospital EMRs and is also distributed via Roche's Navify Algorithm Suite. The platform and product together enable precision medicine in acute care by combining biological data with clinical data to generate real-time predictive insights.

Product and service2 records
1Immunix® Precision Medicine Platform
CategoryPrecision Medicine Platform / Software
Description

Precision medicine platform that combines a proprietary biobank of over 138,000 longitudinal specimens and clinical data from 35,000+ patients across more than 11 U.S. hospitals to build AI-powered diagnostic and predictive tools for acute care conditions including sepsis, ARDS, AKI, and AHF. Targets hospital systems, academic medical centers, and pharmaceutical/diagnostic partners developing precision medicine solutions.

2Sepsis ImmunoScore®
CategoryAI Clinical Diagnostic Software
Description

First FDA-authorized AI diagnostic tool for sepsis, using 22 parameters including biomarkers and clinical data to detect sepsis and predict adverse outcomes within 24 hours. Integrates directly into hospital EMRs and is available via Roche's Navify Algorithm Suite. Risk stratifies patients into four discrete categories (Very High, High, Medium, Low Risk). Sold to hospital systems and health networks for use in acute care settings.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Collaboration to identify biological signatures and patient subpopulations that may benefit from BioAegis' gelsolin therapy using Prenosis' precision medicine platform to analyze biospecimens from Phase 2 ARDS clinical trial.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-10
Description

Commercial distribution partnership making Sepsis ImmunoScore available through Roche's Navify Algorithm Suite platform, providing access to Roche's extensive hospital and laboratory customer base across the United States.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Dascena
TypeDirect peer
Description

Dascena develops machine-learning-based algorithms for early prediction of sepsis and other acute conditions in hospital settings. It is a direct competitor pursuing the same AI-enabled in-hospital sepsis prediction use case as Prenosis.

TypeDirect peer
Description

Cytovale's IntelliSep is an FDA-cleared rapid cellular biomarker diagnostic for sepsis that delivers results in under 10 minutes. Like Prenosis, it sells an FDA-cleared sepsis diagnostic to U.S. hospitals, making it a direct peer in the same product category.

TypeDirect peer
Description

Inflammatix develops host-response-based diagnostics for acute infections and sepsis using machine learning on gene expression data. It targets the same clinical need — rapid, biology-driven sepsis diagnosis — with a complementary biomarker-plus-AI approach.

TypeDirect peer
Description

T2 Biosystems commercializes T2Bacteria, T2Candida, and the T2Dx instrument for direct-from-blood molecular detection of sepsis-causing pathogens. It competes in the same hospital sepsis diagnostic market, though using molecular rather than AI-biomarker methods.

TypeBroad incumbent
Description

bioMérieux's BioFire FilmArray blood culture identification panels are widely deployed in U.S. hospital labs for rapid infectious disease diagnostics. As an established incumbent with broad diagnostic portfolios and large sales coverage, it competes in the same hospital sepsis workup category as Prenosis.

6Tempus AI
TypeBroad incumbent
Description

Tempus AI is a precision medicine platform combining multimodal biological and clinical data with AI to support diagnostics and therapeutics across multiple disease areas. It is a broader incumbent in data-driven precision medicine, overlapping with Prenosis's Immunix platform thesis.

TypeEmerging player
Description

Viz.ai commercializes FDA-authorized AI algorithms integrated into hospital workflows for time-sensitive conditions (notably stroke). It is comparable as an emerging AI diagnostics company selling into the same enterprise hospital IT channel with EMR-embedded FDA-cleared algorithms.

TypeEmerging player
Description

Digital Diagnostics pioneered FDA-authorized autonomous AI diagnostics (IDx-DR for diabetic retinopathy). It is comparable to Prenosis as a peer in the small group of companies with de novo FDA authorizations for AI clinical diagnostics.

TypeBroad incumbent
Description

DeepHealth, acquired by RadNet, develops AI-powered diagnostic imaging software deployed across large hospital and imaging-center networks. It is comparable as a broader AI diagnostics incumbent selling into the same enterprise healthcare channel.

TypeEmerging player
Description

Cleerly is an AI diagnostics company with FDA-cleared tools for cardiovascular disease detection integrated into clinical workflows. It is comparable as an emerging AI diagnostics peer pursuing FDA-authorized, EMR-integrated specialty diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prenosis

AI Clinical Diagnostics for Acute Careprenosis.com

Prenosis is a Chicago-based AI diagnostics company that developed Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, built on its Immunix precision medicine platform combining a 138,000+ specimen biobank with clinical data, sold to U.S. hospital systems and distributed via Roche Diagnostics.

What Prenosis does

Prenosis is a Chicago-based AI diagnostics company founded in 2014 that develops precision medicine tools for acute care conditions, with its first commercial focus on sepsis. The company's lead product, the Sepsis ImmunoScore, is the first FDA-authorized AI diagnostic tool for sepsis (De Novo authorization, April 2024); it ingests 22 parameters including vital signs, routine labs, demographics, and biomarkers (CRP, procalcitonin) to predict sepsis onset and adverse outcomes within 24 hours, stratifying patients into four risk levels, and achieved an AUC of 0.82 in NEJM AI peer-reviewed validation. The Sepsis ImmunoScore is built on the Immunix precision medicine platform, which combines biological data from over 138,000 longitudinal blood specimens with clinical EMR data from 35,000+ patients collected across 11+ U.S. hospitals over more than a decade — claimed as the world's largest biological-clinical dataset for acute care patients with suspected infections.

Prenosis generates revenue through a combination of subscription/recurring AI diagnostic testing deployed via direct enterprise sales to hospital systems, platform licensing through an exclusive commercial distribution partnership with Roche Diagnostics via the Navify Algorithm Suite, and clinical trial network services supporting BARDA-funded studies. Its customer base is concentrated in U.S. large hospital systems, academic medical centers, and government healthcare programs (BARDA, NIH, DTRA), with the U.S. military and federal agencies representing adjacent non-dilutive funding channels. The company's primary GTM motions combine enterprise field sales targeting integrated delivery networks, channel distribution through Roche's established diagnostic footprint, and event-driven engagement with the sepsis and emergency medicine clinical community (Sepsis Alliance Summit, ACEP, World Sepsis Congress).

Strategically, Prenosis is positioned to extend beyond sepsis into adjacent acute care conditions (ARDS, AKI, AHF) using its Immunix platform, with a $20M BARDA Type to Treat Program contract funding expansion to up to 40 U.S. academic medical centers and a co-development collaboration with BioAegis Therapeutics for ARDS patient stratification. Recent milestones including SOC 2 Type II compliance (March 2026), a dedicated CMS ICD-10-PCS reimbursement code (effective October 2025), and a $20M Series A financing (January 2026) indicate the company is transitioning from a research-stage biobank operator to a scaled commercial diagnostics platform.

Prenosis firmographics

Firmographics
Name
Prenosis
Legal name
Prenosis, Inc.
Website
https://prenosis.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Prenosis is a Chicago-based AI diagnostics company that developed Sepsis ImmunoScore, the first FDA-authorized AI diagnostic for sepsis, built on its Immunix precision medicine platform combining a 138,000+ specimen biobank with clinical data, sold to U.S. hospital systems and distributed via Roche Diagnostics.
Ownership category
akta.pro rank

Where Prenosis is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prenosis business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. AI Diagnostic Testing: Revenue generated from deployment of Sepsis ImmunoScore diagnostic tool to hospitals and healthcare systems. Tool integrates into hospital EMR workflow and generates risk assessments for patients.
  2. Platform Licensing: Licensing of Immunix platform technology through distribution agreement with Roche Diagnostics for access to Sepsis ImmunoScore via Navify Algorithm Suite.
  3. Clinical Trial Services: Precision medicine clinical trial network services enabling rapid identification of patients with specific biological profiles for therapeutic clinical trials, supporting BARDA-funded studies.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Prenosis product offering

Product offering

Core offering

Prenosis develops and sells AI-powered diagnostic and predictive tools for acute care, primarily through its Sepsis ImmunoScore® product, the first FDA-authorized AI diagnostic for sepsis. The product is built on the proprietary Immunix® precision medicine platform that combines biological data from a large biobank with clinical EMR data. Products are sold to hospital systems via direct enterprise sales and through a distribution partnership with Roche Diagnostics, integrating directly into hospital EMRs.

Product overview

Prenosis offers a two-product portfolio built on its Immunix precision medicine platform: the Immunix platform itself (a biomarker-clinical data platform powering AI diagnostics) and Sepsis ImmunoScore (the first FDA-authorized AI diagnostic tool for sepsis, built on Immunix). Sepsis ImmunoScore integrates directly into hospital EMRs and is also distributed via Roche's Navify Algorithm Suite. The platform and product together enable precision medicine in acute care by combining biological data with clinical data to generate real-time predictive insights.

Differentiator

Problem solved

Functional benefit

Brands

  • Immunix®: Precision medicine platform that enables the development and validation of new precision medicine solutions and their real-time implementation in clinical workflows.
  • Sepsis ImmunoScore®

Products and services

  • Immunix® Precision Medicine Platform Precision medicine platform that combines a proprietary biobank of over 138,000 longitudinal specimens and clinical data from 35,000+ patients across more than 11 U.S. hospitals to build AI-powered diagnostic and predictive tools for acute care conditions including sepsis, ARDS, AKI, and AHF. Targets hospital systems, academic medical centers, and pharmaceutical/diagnostic partners developing precision medicine solutions.
  • Sepsis ImmunoScore® First FDA-authorized AI diagnostic tool for sepsis, using 22 parameters including biomarkers and clinical data to detect sepsis and predict adverse outcomes within 24 hours. Integrates directly into hospital EMRs and is available via Roche's Navify Algorithm Suite. Risk stratifies patients into four discrete categories (Very High, High, Medium, Low Risk). Sold to hospital systems and health networks for use in acute care settings.

Quantifiable outcome

  • 15% higher accuracy in identifying patients meeting Sepsis-3 criteria compared to provider assessment alone
  • +4 more outcomes

Companies that use Prenosis

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Prenosis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature3 records

Prenosis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered strategic and core.

  • BioAegis TherapeuticsstrategicStrategic or Co-development Partner · 21 April 2026Collaboration to identify biological signatures and patient subpopulations that may benefit from BioAegis' gelsolin therapy using Prenosis' precision medicine platform to analyze biospecimens from Phase 2 ARDS clinical trial.
  • Roche DiagnosticscoreChannel Partner/ Reseller/ Distributor · 10 April 2024Commercial distribution partnership making Sepsis ImmunoScore available through Roche's Navify Algorithm Suite platform, providing access to Roche's extensive hospital and laboratory customer base across the United States.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Prenosis competitors and assessment

Company assessment

Direct peers

  • Dascena: Dascena develops machine-learning-based algorithms for early prediction of sepsis and other acute conditions in hospital settings. It is a direct competitor pursuing the same AI-enabled in-hospital sepsis prediction use case as Prenosis.
  • Cytovale: Cytovale's IntelliSep is an FDA-cleared rapid cellular biomarker diagnostic for sepsis that delivers results in under 10 minutes. Like Prenosis, it sells an FDA-cleared sepsis diagnostic to U.S. hospitals, making it a direct peer in the same product category.
  • Inflammatix: Inflammatix develops host-response-based diagnostics for acute infections and sepsis using machine learning on gene expression data. It targets the same clinical need — rapid, biology-driven sepsis diagnosis — with a complementary biomarker-plus-AI approach.
  • T2 Biosystems: T2 Biosystems commercializes T2Bacteria, T2Candida, and the T2Dx instrument for direct-from-blood molecular detection of sepsis-causing pathogens. It competes in the same hospital sepsis diagnostic market, though using molecular rather than AI-biomarker methods.

Broad incumbents

  • bioMérieux (BioFire Diagnostics): bioMérieux's BioFire FilmArray blood culture identification panels are widely deployed in U.S. hospital labs for rapid infectious disease diagnostics. As an established incumbent with broad diagnostic portfolios and large sales coverage, it competes in the same hospital sepsis workup category as Prenosis.
  • Tempus AI: Tempus AI is a precision medicine platform combining multimodal biological and clinical data with AI to support diagnostics and therapeutics across multiple disease areas. It is a broader incumbent in data-driven precision medicine, overlapping with Prenosis's Immunix platform thesis.
  • DeepHealth (RadNet): DeepHealth, acquired by RadNet, develops AI-powered diagnostic imaging software deployed across large hospital and imaging-center networks. It is comparable as a broader AI diagnostics incumbent selling into the same enterprise healthcare channel.

Emerging players

  • Viz.ai: Viz.ai commercializes FDA-authorized AI algorithms integrated into hospital workflows for time-sensitive conditions (notably stroke). It is comparable as an emerging AI diagnostics company selling into the same enterprise hospital IT channel with EMR-embedded FDA-cleared algorithms.
  • Digital Diagnostics (formerly IDx): Digital Diagnostics pioneered FDA-authorized autonomous AI diagnostics (IDx-DR for diabetic retinopathy). It is comparable to Prenosis as a peer in the small group of companies with de novo FDA authorizations for AI clinical diagnostics.
  • Cleerly: Cleerly is an AI diagnostics company with FDA-cleared tools for cardiovascular disease detection integrated into clinical workflows. It is comparable as an emerging AI diagnostics peer pursuing FDA-authorized, EMR-integrated specialty diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Prenosis social profiles

Digital presence

Prenosis compliance and trust

Trust signal

Compliance1 record

Prenosis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prenosis leadership team

Management profile

Number of profiles

Profiles12 records

Prenosis funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prenosis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prenosis

What does Prenosis do?

Prenosis develops and sells AI-powered diagnostic and predictive tools for acute care, primarily through its Sepsis ImmunoScore® product, the first FDA-authorized AI diagnostic for sepsis. The product is built on the proprietary Immunix® precision medicine platform that combines biological data from a large biobank with clinical EMR data. Products are sold to hospital systems via direct enterprise sales and through a distribution partnership with Roche Diagnostics, integrating directly into hospital EMRs.

Is Prenosis a public or private company?

Prenosis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prenosis founded?

Prenosis was founded in 2014. It employs 11 to 50 people.

Where is Prenosis based?

Prenosis is headquartered in Chicago, United States, in the North America region.

How does Prenosis make money?

Three revenue lines are on record. AI Diagnostic Testing is the primary driver. The others are platform Licensing and clinical Trial Services.

Who are Prenosis's main competitors?

Direct peers on record are Dascena, Cytovale, Inflammatix and T2 Biosystems. Broad incumbents are bioMérieux (BioFire Diagnostics), Tempus AI and DeepHealth (RadNet). Emerging players are Viz.ai, Digital Diagnostics (formerly IDx) and Cleerly.

Does Prenosis have an API?

No public API is recorded for Prenosis.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePrenosis and Carle Health Mark Sepsis ImmunoScore® Clinical Deployment and First Patients Enrolled in OBSERVE-ARDS Clinical StudyCarle Health became the first site in Prenosis' OBSERVE-ARDS study, enrolling the first patients. The study uses Prenosis' Immunix platform integrated with Carle's EHR to screen and recruit patients. Carle plans to join the company's Steroid Therapy Optimization for Prevention of Acute Respiratory Distress Syndrome (STOP ARDS) study.MobiHealthNewsHIMSSCast: Prenosis CEO on using AI to detect sepsisPrenosis CEO Dr. Bobby Reddy Jr. discussed the company's AI-based Sepsis ImmunoScore, which analyzes patient data to assess sepsis risk. He noted the tool is a diagnostic but does not guide treatment, and said Prenosis plans to expand into companion diagnostics and novel therapeutics.AijournPrenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq BellPrenosis will join Chicago Innovation Awards winners in New York City on August 31 to ring the Nasdaq bell. The company's Sepsis ImmunoScore is the first FDA-authorized AI diagnostic for sepsis, detecting the condition within 24 hours. The company aims to tailor treatments based on each patient's biology.PR NewswirePrenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq BellPrenosis will ring the Nasdaq bell with other Chicago Innovation Awards winners in New York on August 31. Its Sepsis ImmunoScore is the first FDA-authorized AI diagnostic for sepsis, detecting the condition within 24 hours. The company aims to tailor precision therapeutics to each patient's biology.AdvfnPrenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq BellPrenosis, a precision therapeutics company, will join Chicago Innovation Awards winners in New York City on August 31 to ring the Nasdaq bell. Its Sepsis ImmunoScore is the first FDA-authorized AI diagnostic for sepsis, detecting the condition within 24 hours. The company aims to tailor treatments based on each patient's biology.MorningstarPrenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq BellPrenosis will join Chicago Innovation Awards winners in New York City on August 31 to ring the Nasdaq bell. The company's Sepsis ImmunoScore is the first FDA-authorized AI diagnostic for sepsis, detecting the condition within 24 hours. The company aims to tailor treatments based on each patient's biology.TipranksAI-Driven Precision Medicine Focus in Acute Care at Prenosis IncPrenosis Inc CEO Bobby Reddy Jr. and clinician Nate Shapiro discussed AI-driven precision medicine for acute conditions like sepsis, ARDS, and acute kidney injury. The post suggests AI could segment patients and enable targeted interventions, but no specific products, regulatory milestones, or revenue traction were disclosed.TipranksPrecision Medicine Focus Highlights Prenosis Inc’s AI-Driven Acute Care StrategyPrenosis Inc highlighted a podcast discussion on precision medicine in acute care, emphasizing real-time biomarkers and AI to guide treatment selection. The company aims to develop data-driven clinical decision support tools, targeting hospitals seeking improved outcomes and cost efficiencies through advanced analytics.TipranksPrenosis Targets Senior Business Analyst Hire to Support AI Precision Medicine PlatformPrenosis Inc. is hiring a Principal Business Analyst to support its AI-powered precision medicine platform, focusing on requirements lifecycle in a regulated healthcare environment. The role requires over seven years of experience and is remote-friendly with Chicago headquarters. The hire may support product development and compliance-ready processes.TipranksPrenosis Inc – Weekly RecapPrenosis Inc deployed its FDA-authorized Sepsis ImmunoScore AI tool at LifeBridge Health's Sinai Hospital of Baltimore for bedside sepsis detection. The company also expanded a collaboration with LifeBridge Health to develop AI-driven bedside solutions for critical conditions. The deployment provides early commercial validation and real-world evidence for future adoption.